A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Lorvotuzumab mertansine (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 21 Mar 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 21 Mar 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 21 Mar 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.